公开(公告)号：US20250032497A1

公开(公告)日：2025-01-30

申请号：US18904007

申请日：2024-10-01

Applicant: Mirati Therapeutics, Inc.

Inventor： Jacob Haling ,  John Michael Ketcham ,  Shilpi Khare

IPC: A61K31/519 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRas G12C inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.

公开(公告)号：US20240408098A1

公开(公告)日：2024-12-12

申请号：US18694848

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/4439 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers: in particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a PI3Ka inhibitor and a KRas G12D inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use thereof.

公开(公告)号：US20240391882A1

公开(公告)日：2024-11-28

申请号：US18658666

申请日：2024-05-08

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Christopher Ronald Smith ,  John Michael Ketcham ,  Stephen Harwood ,  Aaron Craig Burns ,  John David Lawson ,  Kersti Caddell-Haatveit

IPC: C07D241/44 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/048 ,  C07D491/08 ,  C07D491/107 ,  C07D491/147 ,  C07D491/18 ,  C07D495/04 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/20 ,  C07D513/04

Abstract: Disclosed herein are substituted quinoxalines, methods for their preparation, and use thereof.

公开(公告)号：US11999753B2

公开(公告)日：2024-06-04

申请号：US17553224

申请日：2021-12-16

Applicant: Mirati Therapeutics, Inc.

Inventor： Xiaolun Wang ,  Anthony Ivetac ,  Svitlana Kulyk ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D471/04 ,  A61K31/519 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240034733A1

公开(公告)日：2024-02-01

申请号：US18034852

申请日：2021-11-02

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Matthew Arnold Marx ,  John David Lawson ,  Patrick Michael Doerner Barbaur ,  James Francis Blake ,  Jay Bradford Fell ,  John Peter Fischer ,  Bradley J. Newhouse ,  Phong Nguyen ,  Jacob M. O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Tony Pisal Tang

IPC: C07D471/08 ,  C07D519/00 ,  C07D403/12

CPC classification number: C07D471/08 ,  C07D519/00 ,  C07D403/12

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230383359A1

公开(公告)日：2023-11-30

申请号：US18032492

申请日：2021-10-21

Applicant: Mirati Therapeutics, Inc.

Inventor： James Gail Christensen ,  Andrew Chi ,  Thian Kheoh

IPC: C12Q1/6886 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention relates to methods for treatment of lung cancers, in particular non-small cell lung cancer (NSCLC), wherein lung cancers have both a KRAS G12C mutation and an STK11 mutation, with adagrasib (MRTX849).

公开(公告)号：US20230357277A1

公开(公告)日：2023-11-09

申请号：US18027300

申请日：2021-09-21

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  Shelley Allen ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Michael Christopher Hilton ,  Dean Russell Kahn ,  Macedonio Junior Mejia ,  Phong Nguyen ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Yu Savechenkov ,  Tony Pisal Tang

IPC: C07D519/00 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230339976A1

公开(公告)日：2023-10-26

申请号：US18020013

申请日：2021-08-03

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  John David Lawson ,  Shelley Allen ,  Patrick Michael Barbour ,  James Francis Blake ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Sherif Hosam Hassanien ,  Michael Christopher Hilton ,  Macedonio Junior Mejia ,  Jacob Matthew O’Leary ,  Tony Pisal Tang

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D519/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230312482A1

公开(公告)日：2023-10-05

申请号：US18018422

申请日：2021-07-27

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Anthony Ivetac

IPC: C07D237/34 ,  C07D409/12

CPC classification number: C07D237/34 ,  C07D409/12

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20230137025A1

公开(公告)日：2023-05-04

申请号：US17822667

申请日：2022-08-26

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold MARX ,  Matthew Randolph LEE ,  Thomas P. BOBINSKI ,  Aaron Craig BURNS ,  Nidhi ARORA ,  James Gail CHRISTENSEN ,  John Michael KETCHAM

IPC: C07D487/04

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.